Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 2
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Alterations in specific signal transduction pathways may explain the increased expression of proinflammatory cytokines seen in inflammatory diseases such as psoriasis. We reveal increased TNF-α protein expression, but similar TNF-α mRNA levels, in lesional compared with nonlesional psoriatic skin, demonstrating for the first time that TNF-α expression in lesional psoriatic skin is regulated posttranscriptionally. Increased levels of activated MAPK-activated protein kinase 2 (MK2) together with increased MK2 kinase activity were found in lesional compared with nonlesional psoriatic skin. Immunohistochemical analysis showed that activated MK2 was located in the basal layers of the psoriatic epidermis, whereas no positive staining was seen in nonlesional psoriatic skin. In vitro experiments demonstrated that both anisomycin and IL-1β caused a significant activation of p38 MAPK and MK2 in cultured normal human keratinocytes. In addition, TNF-α protein levels were significantly up-regulated in keratinocytes stimulated with anisomycin or IL-1β. This increase in TNF-α protein expression was completely blocked by the p38 inhibitor, SB202190. Transfection of cultured keratinocytes with MK2-specific small interfering RNA led to a significant decrease in MK2 expression and a subsequent significant reduction in the protein expression of the proinflammatory cytokines TNF-α, IL-6, and IL-8, whereas no change in the expression of the anti-inflammatory cytokine IL-10 was seen. This is the first time that MK2 expression and activity have been investigated in an inflammatory disease such as psoriasis. The results strongly suggest that increased activation of MK2 is responsible for the elevated and posttranscriptionally regulated TNF-α protein expression in psoriatic skin, making MK2 a potential target in the treatment of psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis
Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H.-D., & Gaestel, M. (1999) · Nature Cell Biology · doi:10.1038/10061 · Cited by 763 · cited 5×
“TNF- has been demonstrated to be regulated at a posttranscriptional level by MK2 (19).”
BackgroundInfluential
Cited by
Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
p38MAPK: stress responses from molecular mechanisms to therapeutics
Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F., & Burchill, S. A. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.005 · Cited by 691
Angiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383
Post-transcriptional control of cytokine production
Anderson, P. (2008) · Nature Immunology · doi:10.1038/ni1584 · Cited by 376
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
Johansen, C., Usher, P. A., Kjellerup, R. B., Lundsgaard, D., Iversen, L., & Kragballe, K. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08902.x · Cited by 352
Self-citationGuilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F.-X., Lecron, J.-C., & Morel, F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902464 · Cited by 353
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Lynde, C. W., Poulin, Y., Vender, R., Bourcier, M., & Khalil, S. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.036 · Cited by 335
The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation
Moens, U., Kostenko, S., & Sveinbjørnsson, B. (2013) · Genes · doi:10.3390/genes4020101 · Cited by 322
The UV response of the skin: a review of the MAPK, NFκB and TNFα signal transduction pathways
Muthusamy, V., & Piva, T. J. (2010) · Archives of Dermatological Research · doi:10.1007/s00403-009-0994-y · Cited by 265
Modulation of mRNA stability as a novel therapeutic approach
Eberhardt, W., Doller, A., Akool, E.-S., & Pfeilschifter, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.002 · Cited by 173
Psoralen and Ultraviolet A Light Therapy for Psoriasis
Stern, R. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmct072317 · Cited by 149
IκBζ is a key driver in the development of psoriasis
Johansen, C., Mose, M., Ommen, P., Bertelsen, T., Vinter, H., Hailfinger, S., Lorscheid, S., Schulze-Osthoff, K., & Iversen, L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509971112 · Cited by 125
Self-citationMolecular basis of MAPK-activated protein kinase 2:p38 assembly
White, A., Pargellis, C. A., Studts, J. M., Werneburg, B. G., & Farmer, B. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701679104 · Cited by 111
Metadata
- Authors
- Johansen, C., Funding, A. T., Otkjaer, K., Kragballe, K., Jensen, U. B., Madsen, M., Binderup, L., Skak-Nielsen, T., Fjording, M. S., & Iversen, L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-01
- Volume
- 176
- Issue
- 3
- Pages
- 1431-1438
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1902683402
- Cited by
- 139
- References
- 1
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.